

HRD Status Report

Sample Report — Case B

CANCER TYPE Peritoneal / Omental Deposit	METHOD DNA Whole Exome Sequencing
QC STATUS PASS	SPECIMEN Peripheral blood (EDTA)
LIBRARY PREP Agilent SureSelect Human All Exon V6	SEQUENCER BGI DNBSEQ

HRD Status

HRD FINAL STATUS

POSITIVE — GIS 69 / 100 (Threshold ≥ 42)

15
LOH

21
TAI

33
LST

HRD status determined using scarHRD, assessing genomic instability across the whole-exome dataset against a pooled healthy-control reference. Genomic Instability Score combines Loss of Heterozygosity (LOH) + Telomeric Allelic Imbalance (TAI) + Large-Scale state Transitions (LST). HRD-positive tumors combined with BRCA1/BRCA2 inactivation are susceptible to PARP inhibitors and platinum chemotherapy.

This is a de-identified sample of NCRO's report output, shared to illustrate report depth and format. All patient, ordering-physician and institution details have been removed. Variant classifications may change as scientific evidence evolves. This sample does not constitute a clinical report for any individual and should not be used for clinical decision-making.